Exhibit 16.1
December 20, 2019
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Ladies and Gentlemen:
We have read the statements of Immunovant, Inc. (formally known as Health Sciences Acquisitions Corporation) included under Item 4.01 of its Form 8-K dated December 18, 2019. We agree with the statements concerning our Firm under Item 4.01, in which we were informed of our dismissal on December 18, 2019. We are not in a position to agree or disagree with other statements contained therein.
Very truly yours, |
/s/ WithumSmith+Brown, PC |
New York, New York |